Drug Profile
MSI 511
Latest Information Update: 14 Aug 2007
Price :
$50
*
At a glance
- Originator Genaera Corporation
- Developer Genaera Corporation; Novartis
- Class Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Aug 2007 Discontinued - Preclinical for Cancer in Switzerland (unspecified route)
- 14 Aug 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 14 Jul 1998 Profile reviewed